January 2022 - Reithera

By ef

Posted January 25, 2022

Strong immunogenicity of heterologous prime-boost immunizations with the experimental vaccine GRAd-COV2 and BNT162b2 or ChAdOx1-nCOV19

Originally published on npj Vaccines volume 6, Article number: 131 (2021). Chiara Agrati, Stefania Capone, Concetta Castilletti, Eleonora Cimini, Giulia Matusali, Silvia Meschi, Eleonora [...]

By ef

In News, Publications

Posted January 24, 2022

GRAd-COV2, a gorilla adenovirus-based candidate vaccine against COVID-19, is safe and immunogenic in younger and older adults

Originally published on Sci Transl Med. 2021 Oct 26. doi: 10.1126/scitranslmed. abj1996.

By ef

In News, Publications

Posted January 23, 2022

Immunogenicity of a new gorilla adenovirus vaccine candidate for COVID-19

Originally published on Molecular Therapy Volume 29, Issue 8, 4 August 2021, Pages 2412-2423 Stefania Capone, Angelo Raggioli, Michela Gentile, Simone Battella, Armin Lahm, Andrea Sommella, [...]

By ef

In News, Publications

Posted January 22, 2022

MAIT cell activation augments adenovirus vector vaccine immunogenicity

Originally published on Science. 2021 Jan 29;371(6528):521-526. doi:10.1126/science.aax8819.PMID: 33510029. Capone S, Brown A, Hartnell F, Sorbo MD, Traboni C, Vassilev V, Colloca S, Nicosia A, [...]

By ef

In News, Publications

Posted January 21, 2022

A next generation vaccine against human rabies based on a single dose of a chimpanzee adenovirus vector serotype C

Originally published on PLoS neglected tropical diseases. 2020 Jul 15. 14(7): e0008459. doi: 10.1371/ journal. pntd.0008459.